Peer-reviewed veterinary case report
Flat-Coated Retriever with Skin Cancer Treated by Doxorubicin
By Montesanto, Christen et al.·Published in Journal of the American Animal Hospital Association·2023·From the University of Wisconsin-Madison School of Veterinary Medicine·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Metastatic Cutaneous Langerhans Cell Histiocytosis in a Flat-Coated Retriever Treated with Doxorubicin and Prednisone.
- Species:
- dog
Plain-English summary
A 2-year-old female flat-coated retriever was brought in for skin problems on her muzzle, which were diagnosed as a type of cancer called cutaneous Langerhans cell histiocytosis. After starting treatment with chemotherapy and prednisone, her condition worsened, so the vet switched to a different chemotherapy drug, doxorubicin. This treatment initially helped, leading to a complete remission for a while, but unfortunately, the cancer returned, and the dog’s health declined. Sadly, she was euthanized due to her worsening condition about four months after her diagnosis.
People also search for: flat-coated retriever skin cancer treatment · doxorubicin for dog cancer · prednisone side effects in dogs
Abstract
A 2 yr old female intact flat-coated retriever dog was presented for evaluation of a histologically diagnosed cutaneous Langerhans cell histiocytosis of the muzzle with right mandibular nodal metastasis and suspected prescapular lymph node metastasis. Chemotherapy (lomustine 60 mg/m2 by mouth as a single dose) and glucocorticoid therapy (prednisone ∼20 mg/m2 by mouth every 24 hr) were initiated. Progressive disease occurred 21 days after lomustine administration. Doxorubicin (at 30 mg/m2 IV every 3 wk) was administered as a second-line therapy. Prednisone was continued at the same dose. Partial response was noted 1 wk after initiation of doxorubicin and sustained through doxorubicin #2. Complete remission was achieved following doxorubicin #3 (63 days from the start of doxorubicin rescue therapy). Progressive disease was noted after doxorubicin #5, for a total duration of response to doxorubicin of 105 days. Further rescue treatment with vinorelbine at 15 mg/m2 IV was elected. Progressive disease and clinical decline were noted 1 wk after initiation of vinorelbine. The patient was euthanized because of clinical decline 126 days after histopathologic diagnosis and 114 days after chemotherapy treatment was initiated.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/37708474/